Lesson plan
RG-7410
RG-7410 is a trace amine-associated receptor 1 (TAAR1) agonist which was under development for the treatment of schizophrenia but was never marketed. Its route of administration was unspecified. The drug reached phase 1 clinical trials prior to the discontinuation of its development. It was under development by Hoffmann-La Roche. RG-7410 was first disclosed by January 2014 and a phase 1 trial was reported to have been completed by October 2014.
Article summary
RG-7410 is a trace amine-associated receptor 1 (TAAR1) agonist which was under development for the treatment of schizophrenia but was never marketed. Its route of administration was unspecified. The drug reached phase 1 clinical trials prior to the discontinuation of its development. It was under development by Hoffmann-La Roche. RG-7410 was first disclosed by January 2014 and a phase 1 trial was reported to have been completed by October 2014.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.